Zipalertinib Phase 3 PFS Win: Regulatory Path Clear, Pricing Cliff and Numerical Void Remain

REZILIENT3 Trial Achieves Primary Endpoint in NSCLC

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced positive interim results from the global Phase III REZILIENT3 trial. The study evaluated zipalertinib combined with platinum-based chemotherapy as a first-line treatment for 285 adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The trial successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival for patients receiving zipalertinib plus chemotherapy compared to chemotherapy alone. Safety outcomes were manageable. Following these findings, an Independent Data Monitoring Committee recommended unblinding the study, and the companies plan to discuss the results with the US FDA to pursue regulatory approval.

• The Phase III REZILIENT3 trial, assessing zipalertinib in combination with platinum-based chemotherapy, successfully achieved its primary endpoint. Interim analysis revealed a statistically significant and clinically meaningful improvement in progression-free survival for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations, compared to chemotherapy alone.
• The study focused on 285 adults with previously untreated, locally advanced or metastatic non-squamous NSCLC specifically characterized by EGFR exon 20 insertion mutations. Zipalertinib, an oral investigational small molecule designed to inhibit EGFR with exon 20 insertion mutations, was evaluated as a first-line treatment in combination with standard platinum-based chemotherapy.
• Based on these positive interim results, an Independent Data Monitoring Committee recommended unblinding the study. Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics intend to engage with the US Food and Drug Administration (FDA) to discuss these findings and pursue regulatory approval for zipalertinib in combination with chemotherapy for this specific patient group in the US.

Addressing the Challenges in EGFR Exon 20 Insertion NSCLC

EGFR exon 20 insertion mutations account for approximately 10% of all EGFR mutations in NSCLC and present a distinct set of therapeutic challenges that set them apart from classical EGFR-activating mutations. Unlike common sensitizing mutations, these insertions confer broad resistance to established targeted therapies, and the mechanistic basis of this resistance has only been partially elucidated.

• Primary resistance to conventional EGFR TKIs: The majority of EGFR exon 20 insertion mutations are intrinsically insensitive to first- and second-generation TKIs, including gefitinib, erlotinib, and afatinib. The mechanistic underpinning of this resistance remains incompletely understood, though structural analyses of a representative TKI-insensitive mutant (D770_N771insNPG) reveal that the inserted residues form a wedge at the C-helix terminus, stabilizing the active kinase conformation without altering the ATP-binding pocket or increasing TKI affinity — a mechanism distinct from classical sensitizing mutations such as L858R.

• Heterogeneity in mutation-specific sensitivity: Not all exon 20 insertions behave uniformly. EGFR-A763_Y764insFQEA is a notable exception, demonstrating high TKI sensitivity in vitro and clinical responsiveness to erlotinib. This variability underscores the need for mutation-level characterization rather than class-level treatment assumptions, complicating generalized therapeutic decision-making.

• Acquired resistance to exon 20-specific inhibitors: Even with targeted agents such as mobocertinib, acquired resistance emerges through multiple mechanisms, including EGFR amplification (n=6, inclusive of broad copy number gain), EGFR secondary mutations (n=3), and the development of T790M or C797S gatekeeper/resistance mutations — the latter being dependent on the specific underlying exon 20 insertion variant.

• Limited clarity on sequential treatment strategies: Following progression on exon 20 insertion-specific inhibitors, the resistance landscape remains poorly characterized, and the efficacy of subsequent therapies such as amivantamab is not yet established. This gap significantly limits the ability to define evidence-based treatment sequencing for this patient population.

REZILIENT3: Zipalertinib Improves PFS in First-Line EGFR Ex20ins NSCLC

The EXCLAIM-2 trial (NCT04129502) evaluated mobocertinib (160 mg once daily) versus platinum-based chemotherapy (pemetrexed plus cisplatin or carboplatin) in the first-line setting. The trial did not meet its primary endpoint: median progression-free survival was 9.6 months in each arm (HR 1.04, 95% CI 0.77–1.39; P = 0.803), and confirmed objective response rates were comparable at 32% versus 30%, respectively. Median duration of response favored mobocertinib at 12.0 months versus 8.4 months with chemotherapy. On the safety front, diarrhea was the predominant grade ≥3 adverse event with mobocertinib (20% vs. 1%), while hematologic toxicity was more prominent in the chemotherapy arm (decreased neutrophil count: 7% vs. 1%; anemia: 10% vs. 6%). A complementary Phase 1/2 trial (NCT02716116), which included the EXCLAIM expansion cohort, assessed mobocertinib in platinum-pretreated patients (n=114) and demonstrated a confirmed ORR of 28% by IRC assessment, a median duration of response of 17.5 months, median PFS of 7.3 months, and a median OS of 24.0 months — with diarrhea and rash as the most frequently reported treatment-related adverse events.

The CHRYSALIS trial (NCT02609776) investigated amivantamab, an EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion mutations following prior platinum-based therapy. In the dedicated exon 20 insertion cohort (n=81), amivantamab demonstrated an objective response rate of 40%, a median duration of response of 11.1 months (95% CI 9.6–not reached), and a median PFS of 8.3 months. The safety profile was characterized predominantly by EGFR- and MET-related skin and nail toxicities, including rash (86%), paronychia (45%), and stomatitis (21%).

The MOON study, a real-world analysis conducted through an early access program for mobocertinib (n=86), provided important pragmatic insights. The overall ORR was 34% (95% CI 24–45%), with a lower response rate of 27% (95% CI 8–58%) observed in treatment-naïve patients. Median PFS was 5 months and median OS was 12 months, with an intracranial response rate of 13%. Treatment-related adverse events occurred in 95% of patients, with grade ≥3 events in 38% — most notably diarrhea (22%) and rash (8%). Treatment was permanently discontinued in 17% of patients, two of whom died due to treatment-related causes. Notably, women were seven times more likely to discontinue treatment than men, highlighting a clinically meaningful tolerability disparity warranting further investigation.

Zipalertinib's First-Line Win: A New Oral Path for EGFR Exon 20 NSCLC

The landscape for treating non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations has long been challenging. These mutations are known for their innate resistance to many conventional EGFR tyrosine kinase inhibitors (TKIs) and are associated with a poor prognosis, creating a significant unmet need for effective first-line therapies. The recent positive interim results from the Phase III REZILIENT3 trial, evaluating zipalertinib combined with platinum-based chemotherapy, mark a pivotal moment in addressing this challenge. The study successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival.

This success is particularly impactful when viewed against the backdrop of existing therapies. While amivantamab, an intravenous bispecific antibody, has shown superior first-line efficacy when combined with chemotherapy, zipalertinib's profile as an orally available, irreversible EGFR TKI could offer a crucial and convenient alternative. This outcome also stands in stark contrast to the EXCLAIM-2 trial, where another oral TKI, mobocertinib, failed to demonstrate superiority over chemotherapy in the first-line setting. Zipalertinib's prior Phase I/II data also indicated clinically meaningful efficacy in pretreated patients, including those with CNS metastases, suggesting a potentially broad utility.

Looking ahead, the strategic implications are clear. Taiho and Cullinan are now poised to pursue regulatory approval, potentially introducing a new oral standard of care. However, the competitive environment remains a key consideration. The magnitude of zipalertinib's benefit relative to established combination therapies, such as amivantamab plus chemotherapy, will be critical for market differentiation. Furthermore, the literature suggests that EGFR exon 20 insertions exhibit varying sensitivities to different TKIs, implying that zipalertinib's efficacy may not be uniform across all specific exon 20 insertion subtypes. Companies will need to clearly articulate zipalertinib's differentiated profile, emphasizing its oral convenience and robust efficacy in this challenging first-line setting, ultimately aiming to enhance patient access and improve long-term outcomes.